| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
PKMYT1
|
|---|---|
| ln Vitro |
- PKMYT1 Inhibition: (Rac)-RP-6306 (compound 181) demonstrated inhibitory activity against PKMYT1 kinase in biochemical assays, but specific IC₅₀/Ki values were not reported in the patent [1]
- Antiproliferative Activity: The compound showed dose-dependent growth inhibition in cancer cell lines with CCNE1 amplification, but detailed GI₅₀ values and cell line-specific data were not provided [1] |
| ln Vivo |
- Tumor Growth Inhibition: Oral administration of (Rac)-RP-6306 reduced tumor growth in xenograft models of CCNE1-amplified cancers, but specific dose-response data and tumor volume reduction percentages were not disclosed [1]
|
| Enzyme Assay |
- PKMYT1 Kinase Activity Assay: Recombinant PKMYT1 was incubated with ATP and a peptide substrate in the presence of (Rac)-RP-6306. Phosphorylation was detected using radiometric or fluorescent methods, but experimental details (e.g., concentrations, incubation time) were not described [1]
|
| Cell Assay |
- Proliferation Assay: Cancer cells were treated with (Rac)-RP-6306 for 72 hours, and viability was assessed by MTT or crystal violet staining. However, specific cell lines, concentrations, and statistical analyses were not provided [1]
|
| Animal Protocol |
- Xenograft Model: Nude mice bearing CCNE1-amplified tumor xenografts received (Rac)-RP-6306 via oral gavage. Drug formulation (e.g., suspension in 0.5% methylcellulose) and dosing frequency (e.g., daily) were mentioned, but exact doses and tumor measurement intervals were not detailed [1]
|
| ADME/Pharmacokinetics |
- Oral Bioavailability: (Rac)-RP-6306 exhibited moderate oral bioavailability in preclinical species, but specific values (e.g., F%) and pharmacokinetic parameters (e.g., Cmax, t1/2) were not reported [1]
|
| References | |
| Additional Infomation |
- Mechanism of Action: (Rac)-RP-6306 inhibits PKMYT1, disrupting CDK1 activation and inducing mitotic catastrophe in CCNE1-amplified cancer cells [1]
- Synthetic Lethality: The compound targets the synthetic lethal interaction between CCNE1 amplification and PKMYT1 dependency, offering a therapeutic strategy for CCNE1-driven tumors [1] - Clinical Potential: (Rac)-RP-6306 is being evaluated in preclinical models for ovarian, endometrial, and bladder cancers with CCNE1 amplification [1] Lunresertib is an orally bioavailable inhibitor of the human membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (PKMYT1), with potential antineoplastic activity. Upon oral administration, lunresertib targets, binds to and inhibits the activity of PKMYT1. This results in the inhibition of CDK1 phosphorylation, which may promote both premature mitosis and a prolonged mitotic arrest, and lead to the accumulation of unrepaired DNA damage and apoptosis in susceptible tumor cells, such as CCNE1-overexpressing tumor cells. PKMYT1 phosphorylates CDK1 specifically when CDK1 is complexed to cyclins, which blocks progression from G2 into mitosis. |
| Molecular Formula |
C18H20N4O2
|
|---|---|
| Molecular Weight |
324.377003669739
|
| Exact Mass |
324.158
|
| Elemental Analysis |
C, 66.65; H, 6.21; N, 17.27; O, 9.86
|
| CAS # |
2719749-28-5
|
| Related CAS # |
RP-6306;2719793-90-3;(R)-RP-6306;2719793-91-4
|
| PubChem CID |
156869388
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
488
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1=CC=C(C)C(=C1C)N1C(=C(C(N)=O)C2=CC(C)=C(C)N=C12)N
|
| InChi Key |
ARBRHWRTXPWZGN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H20N4O2/c1-8-5-6-13(23)10(3)15(8)22-16(19)14(17(20)24)12-7-9(2)11(4)21-18(12)22/h5-7,23H,19H2,1-4H3,(H2,20,24)
|
| Chemical Name |
2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethylpyrrolo[2,3-b]pyridine-3-carboxamide
|
| Synonyms |
RP-6306; (Rac)-RP-6306; 2719793-90-3; lunresertib; 2719749-28-5; (R)-RP-6306; CHEMBL5199076; N95U3A7N57;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~260 mg/mL (~801.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (3.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (3.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0828 mL | 15.4140 mL | 30.8280 mL | |
| 5 mM | 0.6166 mL | 3.0828 mL | 6.1656 mL | |
| 10 mM | 0.3083 mL | 1.5414 mL | 3.0828 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
